Alzheimer's neuropathology and longitudinal change in subjective cognitive complaints

Alisa Bannerjee[1], Wendy Elkins[1], Susan M. Resnick[1], Murat Bilgel[1]

[1] Laboratory of Behavioral Neuroscience, National Institute on Aging, 251 Bayview Blvd., Baltimore, Maryland, USA, 21224

Corresponding author: Murat Bilgel, murat.bilgel@nih.gov, 251 Bayview Blvd., Suite 100 Rm 04B329, Baltimore, MD, 21224 USA

Abstract

INTRODUCTION: Subjective cognitive complaints often precede declines in objective measures of cognitive performance. Incipient AD neuropathology may be associated with subjective cognitive complaints prior to detectable associations with neuropsychological testing among cognitively normal individuals.

METHODS: We examined the independent associations of PET measures of amyloid-β and tau pathology with longitudinal change in subjective complaints and memory among 91 cognitively normal Baltimore Longitudinal Study of Aging participants using linear mixed effects models. Subjective complaints and memory performance were assessed with the Cognitive Failures Questionnaire and the California Verbal Learning Test, respectively.

RESULTS: Greater parahippocampal tau, independent of amyloid, was associated with higher subjective complaints (estimate=0.203, SE=0.0825, p=0.016), while greater entorhinal tau corresponded to an attenuated increase in complaints over time (estimate=-0.0629, SE=0.0299, p=0.040). Hippocampal tau was associated with steeper memory decline (estimate=-0.0279, SE=0.0135, p=0.043).

CONCLUSION: Subjective cognitive complaints may serve as early indicators of cerebral tau pathology in cognitively normal individuals.

Keywords

Keywords: Tau; amyloid; Aβ; PET; subjective cognitive complaints; Alzheimer's disease; cognitive decline; Cognitive Failures Questionnaire; CFQ; California Verbal Learning Test; CVLT; longitudinal; entorhinal; hippocampus

1   Introduction

Subjective cognitive complaints are individuals' perceived and self-reported memory complaints, or memory complaints reported by a close relative or friend who has observed changes in the individual's cognition [1]. The 2018 National Institute of Aging – Alzheimer's Association Alzheimer's Disease (AD) Research Framework [2] as well as the Alzheimer's Association Workgroup's revised criteria for diagnosis and staging of Alzheimer's disease [3] identify clinical stage 2 as the time when an individual is experiencing subtle cognitive change, which can be measured by subjective cognitive complaints, but does not show cognitive impairment on objective testing. Some studies have shown that participants reporting higher subjective cognitive complaints had worse scores on neuropsychological testing [4,5] and faster rates of decline in neuropsychological testing [6]. In addition, participants with subjective cognitive complaints are at a higher risk for progressing to dementia versus those without these complaints [7–9]. However, other studies did not find an association between subjective cognitive complaints and objective cognitive assessments [10,11].

The revised criteria for AD suggest that for individuals in clinical stage 2, defined by subtle cognitive decline including subjective decline, the typical expected biological stage is B, which is characterized by the presence of amyloid-β plaques and medial temporal tau [3]. This is supported by research showing that individuals with subjective cognitive complaints have higher levels of amyloid and tau in the brain [8]. Detecting these neuropathological changes in early stages is essential as studies have shown that the onset of these changes precede the onset of clinical AD symptoms by up to 15 years for CSF tau and 20 years for CSF Aβ_{42} [12,13]. Furthermore, a study using data from ADNI found that the median time from estimated amyloid onset to clinical AD symptoms, as determined with a Clinical Dementia Rating (CDR) ≥ 1, to be approximately 14 years [14].

Prior research has offered insight into the association between neuropathology and subjective cognitive decline. Amyloid positivity has been associated with higher levels of cognitive complaints even after accounting for depression and anxiety [15,16]. In addition, the severity of subjective cognitive complaints has been associated with higher amyloid burden [17], especially in the parietal and frontal cortices [18] and among *APOE* ε4 carriers [19]. Compared to amyloid, tau pathology is a stronger predictor of cognitive decline and progression to dementia [20–22]. However, there is limited research on the relationship between subjective cognitive complaints and tau pathology. One previous study found that subjective cognitive complaints were associated with tau aggregation, particularly in the frontal and parietal regions [23], while other studies did not find associations with tau pathology [24,25]. Few studies have examined longitudinal outcomes of amyloid and tau pathology in association with subjective cognitive complaints.

Our study focuses on the following three research questions: first, what is the cross-sectional association between AD neuropathology and subjective cognitive complaints in cognitively normal individuals? Second, is AD neuropathology a predictor of subjective cognitive decline over time? Third, is AD neuropathology a stronger predictor of subjective cognitive complaints compared to neuropsychological assessment-based measures of memory among cognitively normal individuals? To address these questions, we assessed the relationship of subjective cognitive complaints as measured by the Cognitive Failures Questionnaire (CFQ) with global amyloid positivity and tau PET levels in regions that are known to exhibit early tau pathology.

2 Methods

2.1 Participants

We used data from 91 cognitively normal participants in the neuroimaging substudy of the Baltimore Longitudinal Study of Aging (BLSA) who had an ^{18}F-flortaucipir (FTP) PET scan to measure phosphorylated tau burden, a ^{11}C-Pittsburgh compound B (PiB) PET scan to measure fibrillar Aβ burden, completed the Cognitive Failures Questionnaire (CFQ) [26], and received the California Verbal Learning Test (CVLT) [27]. We included the first FTP PET assessment per participant in the analyses. For inclusion, participants needed to have a PiB PET within 2 years of their baseline FTP PET as well as a CFQ and a CVLT assessment within 6 months of their baseline FTP or PiB PET. Visits where participants did not answer more than half of the questions on the CFQ (the back of the questionnaire sheet) were

excluded. For the longitudinal analyses, we examined all CFQ and CVLT assessments up to 5 years prior to and following the baseline FTP PET scan.

Participants were cognitively normal at all visits included in the analyses. Enrollment criteria for the neuroimaging substudy included having no evidence of central nervous system disease, severe cardiovascular or pulmonary disease, major psychiatric disorders, or metastatic cancer. Cognitively normal status was based on either (1) a Clinical Dementia Rating [28] of zero and ≤ 3 errors on the Blessed Information-Memory-Concentration Test [29], and therefore, the participant did not meet criteria for a consensus conference; or (2) the participant was determined to be cognitively normal based on thorough review of clinical and neuropsychological data at consensus conference.

Research protocols were conducted in accordance with the United States federal policy for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46), approved by local Institutional Review Boards (IRB) and the National Institutes of Health, and all participants gave written informed consent at each visit. BLSA PET study was governed by the IRB of the Johns Hopkins Medical Institutions (protocol numbers NA_00051793, IRB00047185) and the BLSA study was overseen by the National Institute of Environmental Health Sciences (NIEHS) IRB and the IRB of the Intramural Research Program of the National Institutes of Health (NIH).

2.2 Cognitive measures

The CFQ evaluates subjective cognitive complaints, comprising 25 questions regarding common cognitive issues people may have in their everyday life. Examples of these

questions include: Do you fail to listen to people's names when you are meeting them? Do you have trouble making up your mind? Do you find you forget what you went to the store to buy? These questions are rated on a scale of how often the individual experiences these specific problems within the past two weeks, with 0 being "never" to 4 being "very often." Administration of the CFQ in the BLSA neuroimaging substudy began in 2000. Participants completed the questionnaire during their PET visit. We composed a variable to describe total score as a proportion of sum of scores divided by four times the total number of questions answered (sum of scores / (4 × number of questions answered)) to account for missing responses. Higher scores represent greater subjective cognitive complaints.

Using the loadings reported by Rast et al. [30], we also calculated the three CFQ factor scores reflecting forgetfulness, distractibility, and false triggering as a weighted mean of the individual CFQ scores. For assessments with unanswered questions, the missing questions (and their corresponding weights) were excluded when computing the weighted mean. The distractibility factor is defined by Rast et al. as "being absentminded or easily disturbed in one's focused attention in social situations," and comprises loadings from CFQ items such as "Do you fail to hear people speaking to you when you are doing something else?" and "Do you leave important letters unanswered for days?" The false triggering factor is defined as the "interrupted processing of sequences of cognitive and motor actions," and comprises loadings from CFQ items such as "Do you find you forget why you went from one part of the house to the other?" and "Do you find you forget what you went to the store to buy?" The forgetfulness factor is defined as "a tendency to let go from one's mind something known or planned" and comprises loadings from CFQ items such as "Do you find you forget people's names" and "Do you bump into people?" [30].

Verbal episodic memory was assessed by the CVLT. We quantified immediate recall as the sum of the number of correctly remembered items on the five learning trials. A memory composite score was calculated by averaging the z-scores (described below in the Statistical Analysis subsection) of the CVLT immediate recall and the long delay free recall.

The Center for Epidemiological Studies – Depression (CES-D) [31] scale was used to quantify subjective depressive symptoms. All participants had a CES-D assessment within 2 weeks of baseline FTP tau PET.

2.3 PET imaging

To assess phosphorylated tau burden, FTP PET scans were acquired over 30 min on a Siemens High Resolution Research Tomograph (HRRT) scanner starting 75 min after an intravenous bolus injection of approximately 370 MBq of radiotracer. Dynamic images were reconstructed using ordered subset expectation-maximization to yield 6 time frames of 5 min each with approximately 2.5 mm full-width at half-maximum (FWHM) at the center of the field of view (image matrix = 256 × 256 × 107, voxel size = 1.22 × 1.22 × 1.22 mm^3). Following time frame alignment, the 80–100 min average PET image was partial volume corrected using the region-based voxelwise method [32]. The corrected image was then used to compute standardized uptake value ratio (SUVR) images with inferior cerebellar gray matter as the reference region. FTP PET image analysis workflow is detailed in Ziontz et al. (2019) [33]. We computed the average bilateral SUVR in the entorhinal cortex (EC), hippocampus, parahippocampal gyrus, and the inferior temporal gyrus (ITG). We investigated tau burden as a continuous rather than a dichotomous

variable to be able to examine its subtle effects. One participant with outlying regional tau SUVRs was excluded from analyses (entorhinal SUVR of 2.0 and ITG SUVR of 2.7).

To assess fibrillar Aβ burden, PiB PET scans were obtained over 70 min on either a General Electric (GE) Advance or a Siemens HRRT scanner immediately following an intravenous bolus injection of approximately 555 MBq of radiotracer. Scans acquired on the GE Advance were reconstructed using filtered backprojection with a ramp filter to yield 33 time frames with approximately 4.5 mm FWHM at the center of the field of view (image matrix = 128 × 128 × 35, voxel size = 2 mm × 2 mm × 4.25 mm). Scans acquired on the Siemens HRRT were reconstructed using ordered subset expectation-maximization to yield 33 time frames with approximately 2.5 mm FWHM at the center of the field of view (image matrix = 256 × 256 × 207, voxel size = 1.22 mm × 1.22 mm × 1.22 mm). HRRT scans were smoothed with a 3 mm FWHM isotropic Gaussian kernel and then resampled to bring their spatial resolution closer to that of the GE Advance scans and match their voxel size. Following time frame alignment and co-registration with MRI, distribution volume ratio (DVR) images were computed using a spatially constrained simplified reference tissue model with cerebellar gray matter as the reference region [34]. Mean cortical Aβ burden was calculated as the average of the DVR values in cingulate, frontal, parietal (including precuneus), lateral temporal, and lateral occipital cortical regions, excluding the sensorimotor strip. PiB PET image analysis workflow is described in further detail in Bilgel et al. (2020) [35]. Leveraging longitudinal PiB PET data available on both GE Advance and HRRT scanners for 79 BLSA participants, we estimated the parameters of a linear model mapping mean cortical DVR values between the GE Advance and HRRT scanners and applied this mapping to all HRRT values to harmonize them with the GE Advance values. Individuals were

categorized as PiB −/+ based on a mean cortical DVR threshold of 1.06, which was derived from a Gaussian mixture model fitted to harmonized mean cortical DVR values at baseline.

2.4   Statistical analysis

We fitted linear mixed effects models to assess the associations between longitudinal cognitive outcomes and PET biomarkers at index visit, using a separate model for CFQ and memory and per each of the four tau PET ROIs, yielding a total of 8 models. Inclusion of both amyloid status (PiB −/+) and regional tau SUVR terms allowed for the examination of their independent cross-sectional associations with the outcome (CFQ or memory), and the interactions of each of these terms with time from PET allowed for the examination of their associations with the rate of change in the CFQ and memory outcomes. Age and CES-D at the time of the PET scan, sex, and years of education were included as covariates. We included a random intercept and slope per person. We confirmed our cross-sectional findings using linear regression models, fitted using index visits only (Supplementary Material). Additional supplementary linear mixed effects models investigated each of the three CFQ factors and the CVLT measures that make up the memory composite score (i.e., CVLT immediate recall and long delay free recall) as outcomes. We also assessed whether using a continuous index of global amyloid burden rather than binary amyloid status as a covariate affects the main results.

Prior to fitting the models, each cognitive outcome and continuous PET variable was standardized by subtracting its mean and dividing by its standard deviation. The means and standard deviations for this standardization were computed using a larger cross-sectional BLSA data set of cognitively normal individuals between the ages of 70 and 80,

using the visit closest to age 75 per participant. As a result, the regression coefficients reported for the amyloid and tau variables are standardized coefficients.

Statistical analyses were conducted in R version 4.3.2 [36] using the `lmerTest` package [37]. We checked the fit of all statistical models using the `performance` package [38] to ensure they were not susceptible to outliers and that there were no convergence issues.

2.5 Data availability

Code for performing statistical analyses and generating figures is provided in an open repository (https://gitlab.com/bilgelm/PET-and-CFQ). Data from the BLSA are available upon request from the BLSA website (https://www.blsa.nih.gov). All requests are reviewed by the BLSA Data Sharing Proposal Review Committee.

3 Results

The sample consisted of 91 cognitively normal participants. Table 1 presents participant characteristics at index visit, which is defined by the requirement that they have a PiB PET within 2 years of their baseline FTP PET and a CFQ and a CVLT assessment within 6 months of their baseline FTP PET. A total of 241 visits were included for CFQ and 350 for CVLT (Figure 1).

Table 1: Participant characteristics at index visit. For continuous and categorical variables, we report the median and interquartile range and the N and percentage, respectively.

Characteristic	N = 91
Age (yr)	77 (70, 83)
Female	52 (57%)
White	70 (77%)
Education	18.00 (16.00, 18.00)
APOE ε4+	30 (34%)
PiB+	24 (26%)
Entorhinal tau SUVR	1.06 (0.96, 1.11)
Hippocampal tau SUVR	1.29 (1.18, 1.43)
Parahippocampal tau SUVR	1.01 (0.94, 1.07)
ITG tau SUVR	1.22 (1.16, 1.28)
CES-D	4.0 (1.0, 7.8)
CFQ score (sum of scores / 4 × # answered)	0.28 (0.19, 0.34)
CFQ z-score	-0.13 (-0.88, 0.33)
CVLT long delay free recall	11.0 (9.0, 13.0)
CVLT immediate recall	52 (41, 61)
Memory z-score	0.19 (-0.72, 0.77)
Number of CFQ visits	3 (2, 3)
Number of CVLT visits	4 (3, 5)
CFQ follow-up duration (yr)	3.45 (0.47, 4.50)
CVLT follow-up duration (yr)	5.06 (4.11, 6.71)

Abbreviations: APOE, apolipoprotein E; CES-D, Center for Epidemiological Studies - Depression; CFQ, Cognitive Failures Questionnaire; CVLT, California Verbal Learning Test; ITG, inferior temporal gyrus; PiB, Pittsburgh compound B; SUVR, standardized uptake value ratio.

Figure 1: Longitudinal CFQ (left) and memory (right) scores versus age.

3.1 Subjective cognitive complaints

For 223 out of the 241 CFQ assessments, participants answered all 25 CFQ questions. 17 assessments had one unanswered CFQ question and 1 assessment had two unanswered CFQ questions, with questions 15 and 20 being the most likely ones to be unanswered. The forgetfulness, distractibility, and false triggering factor scores were based on questions without any missingness for 230, 233, and 226 CFQ assessments, respectively.

The CFQ total score variable was z-scored using the mean (0.295) and standard deviation (0.119) computed using a cross-sectional BLSA data set of 147 cognitively normal individuals between the ages of 70 and 80, using the visit closest to age 75 per participant. For z-scoring the forgetfulness, distractibility, and false triggering factor scores, we used

mean = 1.437 (SD = 0.522), mean = 1.108 (SD = 0.492), and mean = 1.139 (SD = 0.494), respectively.

In linear mixed effects models that included age, sex, education, CES-D, amyloid positivity, and regional tau pathology, we did not find any cross-sectional or longitudinal associations between amyloid positivity (independent of tau) and CFQ. In contrast, higher parahippocampal tau SUVR, independent of amyloid status, was associated with higher CFQ at index visit (estimate = 0.203, SE = 0.0825, p = 0.016) (Table 2). Higher entorhinal tau SUVR at index visit was associated with with an attenuated increase in CFQ over time (estimate = -0.0629, SE = 0.0299, p = 0.040) (Figure 2).

Similar to our longitudinal finding based on the total CFQ score, we found a statistically significant association between higher entorhinal tau SUVR, independent of amyloid, and attenuated increase over time in the CFQ false triggering and forgetfulness factors, whereas the cross-sectional association with parahippocampal tau SUVR was observed only for the CFQ distractibility score (Supplementary Material).

Table 2: Estimated coefficients along with their standard errors (SE) and p-values for the tau PET SUVR (i.e., cross-sectional effect) and the tau PET SUVR by time interaction (i.e., longitudinal effect) terms in linear mixed effects models where longitudinal CFQ is the outcome. Each column corresponds to a separate model. * indicates p < 0.05.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.138 (SE = 0.092)	0.096 (SE = 0.087)	0.203 (SE = 0.082)	0.039 (SE = 0.113)
	p = 0.135	p = 0.273	p = 0.014*	p = 0.729
Tau PET SUVR × Time	-0.063 (SE = 0.030)	-0.036 (SE = 0.025)	-0.025 (SE = 0.026)	-0.005 (SE = 0.040)

	Entorhinal	Hippocampus	Parahippocampal	ITG
	p = 0.037*	p = 0.153	p = 0.337	p = 0.907

Figure 2: Longitudinal CFQ trajectories by entorhinal tau SUVR z-score based on linear mixed effects model estimates.

3.2   Verbal episodic memory

For z-scoring the CVLT long delay free recall and immediate recall variables, we used mean = 10.7 (SD = 3.3) and mean = 51.3 (SD = 11.6), respectively, which were computed using a cross-sectional BLSA data set of 957 cognitively normal individuals between the ages of 70 and 80, using the visit closest to age 75 per participant.

In linear mixed effects models that included age, sex, years of education, CES-D, amyloid positivity and regional tau pathology, we did not find any cross-sectional or longitudinal associations between amyloid positivity and memory. Greater hippocampal tau SUVR was associated with a steeper decline in memory over time (estimate = -0.0279, SE = 0.0135, *p* = 0.043) (Table 3).

As a secondary analysis, we investigated the two CVLT components of the memory composite score in separate models (Supplementary Material). Similar to our longitudinal finding based on memory composite score, we found that greater hippocampal tau SUVR was associated with a steeper decline in CVLT free recall long delay.

Table 3: Estimated coefficients along with their standard errors (SE) and p-values for the tau PET SUVR (i.e., cross-sectional effect) and the tau PET SUVR by time interaction (i.e., longitudinal effect) terms in linear mixed effects models where longitudinal memory z-score is the outcome. Each column corresponds to a separate model. * indicates p < 0.05.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	-0.078 (SE = 0.114)	-0.172 (SE = 0.105)	-0.171 (SE = 0.102)	-0.162 (SE = 0.134)
	p = 0.495	p = 0.102	p = 0.095	p = 0.225
Tau PET SUVR × Time	0.002 (SE = 0.016)	-0.028 (SE = 0.013)	-0.002 (SE = 0.014)	0.003 (SE = 0.018)
	p = 0.902	p = 0.040*	p = 0.908	p = 0.879

3.3 Comparison of CFQ and memory models

To examine if AD neuropathology is a stronger predictor of subjective cognitive complaints compared to neuropsychological assessment-based measures of memory among cognitively normal individuals, we compared the goodness of fit of the linear mixed effects models using coefficients of determination. The marginal coefficients of determination (R^2) of the CFQ linear mixed effects models were approximately double that of the memory models (0.32–0.35 vs. 0.14–0.17), indicating better model fit based on the fixed effects for the CFQ models. The conditional coefficients of determination, which incorporate random as well as fixed effects, of the CFQ models were 13% lower than those of the memory

models (0.71–0.72 vs. 0.82–0.82), suggesting that once individual-level deviations from the population average in the level and longitudinal rate of decline are accounted for, memory rather than subjective cognitive complaints is better explained by our models.

To assess if the associations of amyloid and tau neuropathology with subjective cognitive complaints differ from their associations with verbal episodic memory, we tested the equality of the standardized regression coefficients between the CFQ and memory models using Seemingly Unrelated Regression Equations [39]. This analysis was limited to examining cross-sectional effects and we negated CFQ to make its direction consistent with that of memory. The differences between the standardized regression coefficients estimated in the CFQ and memory models were not statistically significant for amyloid group or any of the regional tau SUVRs.

4   Discussion

We investigated the independent associations between PET measurements of two hallmark neuropathologies of AD and subjective cognitive complaints among cognitively normal older individuals, adjusting for age, sex, education, and depressive symptoms. Cross-sectionally, greater tau burden in the parahippocampal gyrus was associated with greater subjective cognitive complaints as assessed using the CFQ. Greater entorhinal tau SUVR was associated with an attenuated increase over a median follow-up duration of 3.4 years. In contrast, greater hippocampal SUVR was associated with a steeper decline in memory performance over a median follow-up duration of 5.1 years. Examination of model goodness of fit suggested that AD neuropathology may be a stronger predictor of subjective

cognitive complaints compared to neuropsychological assessment-based measures of memory among cognitively normal individuals, but when we compared CFQ and verbal memory directly, we did not find statistically significant differences between subjective cognitive complaints and memory scores in terms of their associations with AD neuropathology.

The parahippocampal gyrus is part of the medial temporal lobe, a crucial region for memory processing. In agreement with our findings, several studies have also reported associations between tau in the medial temporal lobe and worse cognitive performance and cognitive decline among cognitively unimpaired individuals [40,41]. An ADNI study similarly found that self-reported complaints measured by the ECog (Measurement of Everyday Cognition) questionnaire were associated with parahippocampal tau burden as well as parietal, frontal, and global tau, although they found the strongest associations in the frontal lobe [23], whereas our study primarily analyzed regions in the temporal lobe. However, this ADNI study included those with mild cognitive impairment whereas we restricted our analysis to include only cognitively unimpaired individuals.

The association between greater entorhinal tau and attenuated increases in CFQ over time may be explained by the possibility that subjective cognitive complaints exhibit steep increases early, prior to the elevation in entorhinal tau burden, with the rate of increase in subjective cognitive complaints tapering off later as entorhinal tau burden increases (Figure 3). This possible explanation accounts for both the cross-sectional associations we observed, with higher tau burden being associated with greater subjective cognitive complaints, and the association of higher tau burden with attenuated increases in

subjective cognitive complaints. Another possible explanation for this association is that as an individual experiences advancing pathology and presumably poorer objective memory, they may experience a lack of insight into their cognitive deficits, resulting in a greater denial of symptoms. Larger studies examining both subjective cognitive complaints and tau burden longitudinally will be needed to test these hypotheses.

Figure 3: A possible explanation of the observed cross-sectional and longitudinal associations between tau PET SUVR and CFQ. The trajectories shown in panel A for tau (blue) and CFQ (red) yield a positive cross-sectional association between tau and CFQ as shown in panel B and a negative association between tau and rate of change in CFQ as shown in panel C.

Compared to the total CFQ score, the CFQ distractibility factor, but not false triggering or forgetfulness, had a similar magnitude of association, indicating that our cross-sectional finding may be driven by distractibility [30]. Conversely, we found a statistically significant association between entorhinal tau and the longitudinal rate of change in the false triggering and forgetfulness factors, but not distractibility.

Our findings differ from previous reports in several ways. First, a Harvard Aging Brain Study found that entorhinal tau PET was associated with subjective cognitive decline as

measured by the Memory Functioning Questionnaire, Everyday Cognition battery, and a 7-item questionnaire [42], whereas we did not find such an association with entorhinal tau. In addition, we did not find a relationship between amyloid positivity and longitudinal change in memory, in contrast to longitudinal studies that have consistently indicated this association [43,44], including from the BLSA [45]. This is likely attributable to our inclusion of participants who remained cognitively normal throughout the longitudinal follow-up period included in these analyses and our limited sample size. Because we restricted the sample to cognitively normal participants, the effect of amyloid and tau on verbal memory decline was likely subtle, therefore requiring a larger sample size to detect a statistically significant association. We note, however, that the effect we estimated was in the expected direction. Additionally, the present study adjusted for regional tau pathology in the amyloid models, whereas the previous analysis in the BLSA did not. Second, unlike a previous BLSA analysis that found that elevated baseline entorhinal tau was linked to steeper memory decline prior to tau PET [33], we did not find an association between entorhinal tau and rate of memory decline. This difference may be attributed to the extent of CVLT follow-up in the present study compared with the Ziontz et al. study, as we limited the inclusion of CVLT scores to within five years of their index tau PET visit. In our models, amyloid and tau pathologies were assumed to have additive effects on the outcomes we investigated, but research suggests that their effects might be synergistic, with individuals having both pathologies exhibiting steeper cognitive decline. However, we were unable to investigate this synergistic effect due to our limited sample size.

This study has limitations. Our study accounted for certain factors that are associated with subjective cognitive complaints, such as severe psychiatric or neurological disorders, which

are exclusion criteria for the BLSA, and depressive symptoms, which we adjusted for using CES-D as a covariate. However, there may be other conditions that affect subjective cognitive complaints that we did not account for, such as personality, medication use, substance use, and cultural background. For instance, one study found that CFQ was more associated with personality domains, such as conscientiousness and neuroticism, rather than objective cognitive performance [10]. In addition, our PET measures, particularly in the hippocampus, may be confounded by spill-over of non-specific binding signal in the choroid plexus. Lastly, the BLSA cohort is a highly educated, healthy sample largely comprising White participants. Therefore, it is uncertain how these findings will generalize to a more socioeconomically diverse cohort.

Our study also has important strengths. This study extensively characterized participants through our available longitudinal CFQ measures. We made a direct comparison between subjective and objective measures by investigating associations of tau pathology with CFQ and CVLT. We also created a proportion variable to include those who had missing items on the questionnaire to maximize our sample size. In addition, we used subjective cognitive complaints as a continuous variable, unlike other studies that used subjective cognitive measures to identify participants as part of a subjective cognitive impairment group and then compared to healthy, MCI, and AD groups.

In conclusion, these findings add to our growing knowledge of the relationship between AD pathology and cognition. A previous BLSA study found that subjective cognitive complaints, also measured by the CFQ, were predictive of declining cognitive performance, particularly in verbal memory [6]. Other studies have found that those with subjective memory

complaints combined with baseline AD neuropathology may be more likely to develop dementia and cognitive decline subsequently [46,47]. Therefore, our findings support the utility of including measures of subjective cognitive assessments as early indicators for AD. Early amyloid and tau accumulation may have cognitive effects that could be detected through subjective cognitive questionnaires such as the CFQ. This is of great clinical importance, as in routine clinical practice, amyloid and tau PET scans are not typically acquired; thus, subjective cognitive questionnaires might be a more practical screening tool to determine if further testing is warranted. Future studies investigating the relationship between AD neuropathology and subjective cognitive complaints, particularly among larger and more diverse cohorts, can help clinicians detect those at risk for developing AD at the earliest opportunity and develop targeted interventions.

5   References

[1]   Jessen F, Amariglio RE, Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia 2014;10:844–52. https://doi.org/10.1016/j.jalz.2014.01.001.

[2]   Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018.

[3]   Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for

diagnosis and staging of alzheimer's disease: Alzheimer's association workgroup.

Alzheimer's and Dementia 2024. https://doi.org/10.1002/alz.13859.

[4]   Amariglio RE, Townsend MK, Grodstein F, Sperling RA, Rentz DM. Specific subjective

memory complaints in older persons may indicate poor cognitive function. Journal of the

American Geriatrics Society 2011;59:1612–7. https://doi.org/10.1111/j.1532-

5415.2011.03543.x.

[5]   Park S, Lee JH, Lee J, Cho Y, Park HG, Yoo Y, et al. Interactions between subjective

memory complaint and objective cognitive deficit on memory performances. BMC

Geriatrics 2019;19:294. https://doi.org/10.1186/s12877-019-1322-9.

[6]   Hohman TJ, Beason-Held LL, Lamar M, Resnick SM. Subjective cognitive complaints

and longitudinal changes in memory and brain function. Neuropsychology 2011;25:125–

30. https://doi.org/10.1037/a0020859.

[7]   Gifford KA, Liu D, Lu Z, Tripodis Y, Cantwell NG, Palmisano J, et al. The source of

cognitive complaints predicts diagnostic conversion differentially among nondemented

older adults. Alzheimer's and Dementia 2014;10:319–27.

https://doi.org/10.1016/j.jalz.2013.02.007.

[8]   Kryscio RJ, Abner EL, Cooper GE, Fardo DW, Jicha GA, Nelson PT, et al. Self-reported

memory complaints implications from a longitudinal cohort with autopsies. 2014.

[9]   Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and

mild cognitive impairment in older people with subjective memory complaints: Meta-

analysis. Acta Psychiatrica Scandinavica 2014;130:439–51.

https://doi.org/10.1111/acps.12336.

[10]   Könen T, Karbach J. Self-reported cognitive failures in everyday life: A closer look at

their relation to personality and cognitive performance. Assessment 2020;27:982–95.

https://doi.org/10.1177/1073191118786800.

[11]   Xu Y, Warwick J, Eramudugolla R, Huque H, Anstey KJ, Peters R. No clear

associations between subjective memory concerns and subsequent change in cognitive

function: The PATH through life study. European Journal of Ageing 2022;19:1181–8.

https://doi.org/10.1007/s10433-022-00694-2.

[12]   Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and

biomarker changes in dominantly inherited Alzheimer's disease. New England Journal of

Medicine 2012;367:795–804. https://doi.org/10.1056/nejmoa1202753.

[13]   Buchhave P, Minthon L, Zetterberg H, K Wallin sa, Blennow K, Hansson O.

Cerebrospinal fluid levels of-amyloid 1-42, but not of tau, are fully changed already 5 to 10

years before the onset of Alzheimer dementia. vol. 69. 2012.

[14]   Betthauser TJ, Bilgel M, Koscik RL, Jedynak BM, An Y, Kellett KA, et al. Multi-method

investigation of factors influencing amyloid onset and impairment in three cohorts. Brain

2022;145:4065–79. https://doi.org/10.1093/brain/awac213.

[15]   Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, et al.

Characteristics of subjective cognitive decline associated with amyloid positivity.

Alzheimer's and Dementia 2022;18:1832–45. https://doi.org/10.1002/alz.12512.

[16]   Pavisic IM, Lu K, Keuss SE, James SN, Lane CA, Parker TD, et al. Subjective cognitive complaints at age 70: Associations with amyloid and mental health. Journal of Neurology, Neurosurgery and Psychiatry 2021;92:1215–21. https://doi.org/10.1136/jnnp-2020-325620.

[17]   Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 2012;50:2880–6. https://doi.org/10.1016/j.neuropsychologia.2012.08.011.

[18]   Schwarz C, Lange C, Benson GS, Horn N, Wurdack K, Lukas M, et al. Severity of subjective cognitive complaints and worries in older adults are associated with cerebral amyloid-β load. Frontiers in Aging Neuroscience 2021;13. https://doi.org/10.3389/fnagi.2021.675583.

[19]   Zwan MD, Villemagne VL, Doré V, Buckley R, Bourgeat P, Veljanoski R, et al. Subjective memory complaints in APOE ε4 carriers are associated with high amyloid-β burden. Journal of Alzheimer's Disease 2015;49:1115–22. https://doi.org/10.3233/JAD-150446.

[20]   Ossenkoppele R, Binette AP, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nature Medicine 2022;28:2381–7. https://doi.org/10.1038/s41591-022-02049-x.

[21]   Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 2018;91:e859–66. https://doi.org/10.1212/WNL.0000000000006075.

[22]   Bucci M, Chiotis K, Nordberg A. Alzheimer's disease profiled by fluid and imaging markers: Tau PET best predicts cognitive decline. Molecular Psychiatry 2021;26:5888–98. https://doi.org/10.1038/s41380-021-01263-2.

[23]   Swinford CG, Risacher SL, Charil A, Schwarz AJ, Saykin AJ. Memory concerns in the early alzheimer's disease prodrome: Regional association with tau deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 2018;10:322–31. https://doi.org/10.1016/j.dadm.2018.03.001.

[24]   Müller S, Preische O, Göpfert JC, Yañez VAC, Joos TO, Boecker H, et al. Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. Scientific Reports 2017;7. https://doi.org/10.1038/s41598-017-08779-0.

[25]   Thomas KR, Weigand AJ, Edwards LC, Edmonds EC, Bangen KJ, Ortiz G, et al. Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint. Alzheimer's Research & Therapy 2022;14:114. https://doi.org/10.1186/s13195-022-01060-1.

[26]   Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. British Journal of Clinical Psychology 1982;21:1–6. https://doi.org/10.1111/j.2044-8260.1982.tb01421.x.

[27]   Delis D, Kramer J, Kaplan E, Ober B. California Verbal Learning Test - second edition adult version (CVLT-II). San Antonio, TX: Pearson Clinical Assessment; 2000.

[28]   Morris JC. The Clinical Dementia Rating (CDR). Neurology 1993;43. https://doi.org/10.1212/wnl.43.11.2412-a.

[29]   Fuld P, Katzman R, Terry R, Bick K. Alzheimer's disease: Senile dementia and related disorders 1978.

[30]   Rast P, Zimprich D, Boxtel MV, Jolles J. Factor structure and measurement invariance of the cognitive failures questionnaire across the adult life span. Assessment 2009;16:145–58. https://doi.org/10.1177/1073191108324440.

[31]   Radloff LS. The CES-D scale. Applied Psychological Measurement 1977;1:385–401. https://doi.org/10.1177/014662167700100306.

[32]   Thomas BA, Cuplov V, Bousse A, Mendes A, Thielemans K, Hutton BF, et al. PETPVC: A toolbox for performing partial volume correction techniques in positron emission tomography. Physics in Medicine and Biology 2016;61:7975–93. https://doi.org/10.1088/0031-9155/61/22/7975.

[33]   Ziontz J, Bilgel M, Shafer AT, Moghekar A, Elkins W, Helphrey J, et al. Tau pathology in cognitively normal older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 2019;11:637–45. https://doi.org/10.1016/j.dadm.2019.07.007.

[34]   Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE, et al. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. vol. 36. 2007.

[35]   Bilgel M, Beason-Held L, An Y, Zhou Y, Wong DF, Resnick SM. Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging. Journal of Cerebral Blood Flow and Metabolism 2020;40:288–97. https://doi.org/10.1177/0271678X19830537.

[36]   R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2023.

[37]   Kuznetsova A, Bruun Brockhoff P, Haubo Bojesen Christensen R. lmerTest: Tests in linear mixed effects models. 2020.

[38]   Lüdecke D, Makowski D, Ben-Shachar MS, Patil I, Waggoner P, Wiernik BM. Performance: Assessment of regression models performance. 2023.

[39]   Zellner A. An efficient method of estimating seemingly unrelated regressions and tests for aggregation bias. Journal of the American Statistical Association 1962;57:348–68. https://doi.org/10.1080/01621459.1962.10480664.

[40]   Kwan ATH, Arfaie S, Therriault J, Azizi Z, Lussier FZ, Tissot C, et al. Medial temporal tau predicts memory decline in cognitively unimpaired elderly. Brain Communications 2023;5. https://doi.org/10.1093/braincomms/fcac325.

[41]   Marks SM, Lockhart SN, Baker SL, Jagust WJ. Tau and β-amyloid are associated with medial temporal lobe structure, function, and memory encoding in normal aging. Journal of Neuroscience 2017;37:3192–201. https://doi.org/10.1523/JNEUROSCI.3769-16.2017.

[42]   Buckley RF, Hanseeuw B, Schultz AP, Vannini P, Aghjayan SL, Properzi MJ, et al. Region-specific association of subjective cognitive decline with tauopathy independent of

global β-amyloid burden. JAMA Neurology 2017;74:1455–63.

https://doi.org/10.1001/jamaneurol.2017.2216.

[43]   Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, et al. Cognitive

impairment and decline in cognitively normal older adults with high amyloid-β: A meta-

analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

2017;6:108–21. https://doi.org/10.1016/j.dadm.2016.09.002.

[44]   Mortamais M, Ash JA, Harrison J, Kaye J, Kramer J, Randolph C, et al. Detecting

cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. Alzheimer's

and Dementia 2017;13:468–92. https://doi.org/10.1016/j.jalz.2016.06.2365.

[45]   Bilgel M, An Y, Helphrey J, Elkins W, Gomez G, Wong DF, et al. Effects of amyloid

pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain

2018;141:2475–85. https://doi.org/10.1093/brain/awy150.

[46]   Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sánchez-Valle R, et al. Different

profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with

subjective memory complaints. Journal of Neural Transmission 2011;118:259–62.

https://doi.org/10.1007/s00702-010-0534-0.

[47]   Selnes P, Aarsland D, Bjørnerud A, Gjerstad L, Wallin A, Hessen E, et al. Diffusion

tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial

temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.

Journal of Alzheimer's Disease 2013;33:723–36. https://doi.org/10.3233/JAD-2012-

121603.

6   Acknowledgments

We are grateful to the BLSA participants and staff for their dedication to these studies. We thank Dr. Andrea Shafer for her statistical suggestions in the early stages of our analyses. This research was supported by the Intramural Research Program of the National Institute on Aging, NIH.

7   Consent Statement

All human subjects involved in this study provided informed consent prior to participation.

8   Conflicts of Interest

The authors of this study declare that there are no conflicts of interest related to this work.

Supplementary Material

8.1   Participant selection

Of 113 participants who underwent both amyloid and tau PET imaging, 103 had at least one cognitively normal visit where these two scans were within 2 years of each other. 101 of these participants also had at least one visit with a CES-D assessment within 2 weeks of PET. Of these, 96 had at least one visit where they were cognitively normal at the time of their CFQ assessment. 91 had at least one visit where they had both CFQ and CVLT assessments within 6 months of PET.

8.2   Linear regression models

Linear regression, using index visits only, was used to confirm our cross-sectional associations in the linear mixed effects models. The estimates were similar to those based on the linear mixed effects models.

8.2.1 Subjective cognitive complaints

Figure 4: CFQ score at index visit versus regional tau SUVR.

*Table 4: Linear regression coefficients, their standard errors, and p-values for the tau PET SUVR term for models where CFQ is the outcome. Each column corresponds to a separate model. * indicates p < 0.05.*

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.162 (SE = 0.100)	0.134 (SE = 0.095)	0.250 (SE = 0.089)	0.053 (SE = 0.120)
	p = 0.109	p = 0.164	p = 0.006*	p = 0.658

8.2.2 Verbal episodic memory

Figure 5: Memory z-score at index visit versus regional tau SUVR.

*Table 5: Linear regression coefficients, their standard errors, and p-values for the tau PET SUVR term for models where the outcome is the memory z-score. Each column corresponds to a separate model. * indicates p < 0.05.*

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	-0.024 (SE = 0.121)	-0.087 (SE = 0.114)	-0.118 (SE = 0.109)	-0.097 (SE = 0.142)
	p = 0.841	p = 0.448	p = 0.283	p = 0.499

8.3 Other linear mixed effects models

8.3.1 Subjective cognitive complaints

We repeated the linear mixed effects models using each of the CFQ factors (forgetfulness, distractibility, and false triggering) rather than the total CFQ score as the outcome.

Table 6: Estimated coefficients along with their standard errors (SE) and p-values for the tau PET SUVR (i.e., cross-sectional effect) and the tau PET SUVR by time interaction (i.e., longitudinal effect) terms in linear mixed effects models where longitudinal CFQ forgetfulness is the outcome. Each column corresponds to a separate model. * indicates p < 0.05.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.108 (SE = 0.095)	0.105 (SE = 0.089)	0.163 (SE = 0.085)	0.045 (SE = 0.116)
	p = 0.254	p = 0.242	p = 0.058	p = 0.698
Tau PET SUVR × Time	-0.065 (SE = 0.032)	-0.049 (SE = 0.027)	-0.035 (SE = 0.028)	-0.023 (SE = 0.043)
	p = 0.045*	p = 0.071	p = 0.210	p = 0.590

Table 7: Estimated coefficients along with their standard errors (SE) and p-values for the tau PET SUVR (i.e., cross-sectional effect) and the tau PET SUVR by time interaction (i.e., longitudinal effect) terms in linear mixed effects models where longitudinal CFQ distractibility is the outcome. Each column corresponds to a separate model. * indicates p < 0.05.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.149 (SE = 0.095)	0.111 (SE = 0.090)	0.222 (SE = 0.085)	0.063 (SE = 0.117)
	p = 0.119	p = 0.220	p = 0.010*	p = 0.589
Tau PET SUVR × Time	-0.046 (SE = 0.028)	-0.023 (SE = 0.024)	-0.012 (SE = 0.024)	0.006 (SE = 0.037)
	p = 0.099	p = 0.335	p = 0.609	p = 0.876

Table 8: Estimated coefficients along with their standard errors (SE) and p-values for the tau PET SUVR (i.e., cross-sectional effect) and the tau PET SUVR by time interaction (i.e., longitudinal effect) terms in linear mixed effects models where longitudinal CFQ false triggering is the outcome. Each column corresponds to a separate model. * indicates p < 0.05.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.113 (SE = 0.090)	0.046 (SE = 0.086)	0.156 (SE = 0.082)	0.007 (SE = 0.111)
	p = 0.211	p = 0.596	p = 0.058	p = 0.948
Tau PET SUVR × Time	-0.068 (SE = 0.031)	-0.042 (SE = 0.027)	-0.028 (SE = 0.027)	-0.005 (SE = 0.042)
	p = 0.033*	p = 0.119	p = 0.315	p = 0.907

8.3.2 Verbal episodic memory

We repeated the linear mixed effects models using CVLT immediate recall score and CVLT free recall long delay score as the outcome rather than the memory z-score.

*Table 9: Estimated coefficients along with their standard errors (SE) and p-values for the tau PET SUVR (i.e., cross-sectional effect) and the tau PET SUVR by time interaction (i.e., longitudinal effect) terms in linear mixed effects models where longitudinal CVLT immediate recall is the outcome. Each column corresponds to a separate model. * indicates p < 0.05.*

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	-0.106 (SE = 0.118)	-0.165 (SE = 0.110)	-0.194 (SE = 0.106)	-0.260 (SE = 0.138)
	p = 0.372	p = 0.133	p = 0.068	p = 0.060
Tau PET SUVR × Time	0.000 (SE = 0.018)	-0.024 (SE = 0.015)	-0.002 (SE = 0.016)	-0.016 (SE = 0.021)
	p = 0.998	p = 0.122	p = 0.892	p = 0.425

*Table 10: Estimated coefficients along with their standard errors (SE) and p-values for the tau PET SUVR (i.e., cross-sectional effect) and the tau PET SUVR by time interaction (i.e., longitudinal effect) terms in linear mixed effects models where longitudinal CVLT free recall long delay is the outcome. Each column corresponds to a separate model. * indicates p < 0.05.*

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	-0.051 (SE = 0.115)	-0.181 (SE = 0.105)	-0.149 (SE = 0.104)	-0.065 (SE = 0.136)
	p = 0.654	p = 0.086	p = 0.151	p = 0.632
Tau PET SUVR × Time	0.004 (SE = 0.017)	-0.033 (SE = 0.015)	-0.002 (SE = 0.016)	0.022 (SE = 0.020)
	p = 0.815	p = 0.028*	p = 0.915	p = 0.280

8.3.3 Continuous amyloid burden

We repeated the linear mixed effects models using a continuous amyloid burden index, mean cortical PiB DVR, instead of the binary amyloid status. Our findings remained unchanged.

*Table 11: Estimated coefficients along with their standard errors (SE) and p-values for the tau PET SUVR (i.e., cross-sectional effect) and the tau PET SUVR by time interaction (i.e., longitudinal effect) terms in linear mixed effects models where longitudinal CFQ is the outcome. Instead of binary amyloid status, a continuous amyloid burden index is included as a covariate. Each column corresponds to a separate model. * indicates p < 0.05.*

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	0.141 (SE = 0.091)	0.101 (SE = 0.087)	0.211 (SE = 0.082)	0.062 (SE = 0.113)
	p = 0.125	p = 0.246	p = 0.010*	p = 0.583
Tau PET SUVR × Time	-0.064 (SE = 0.031)	-0.038 (SE = 0.026)	-0.024 (SE = 0.027)	0.002 (SE = 0.041)
	p = 0.040*	p = 0.144	p = 0.368	p = 0.964

Table 12: Estimated coefficients along with their standard errors (SE) and p-values for the tau PET SUVR (i.e., cross-sectional effect) and the tau PET SUVR by time interaction (i.e., longitudinal effect) terms in linear mixed effects models where longitudinal memory z-score is the outcome. Instead of binary amyloid status, a continuous amyloid burden index is included as a covariate. Each column corresponds to a separate model. * indicates p < 0.05.

	Entorhinal	Hippocampus	Parahippocampal	ITG
Tau PET SUVR	-0.074 (SE = 0.112)	-0.167 (SE = 0.104)	-0.170 (SE = 0.101)	-0.175 (SE = 0.132)
	p = 0.510	p = 0.108	p = 0.093	p = 0.187
Tau PET SUVR × Time	0.003 (SE = 0.016)	-0.028 (SE = 0.013)	-0.001 (SE = 0.014)	0.005 (SE = 0.019)
	p = 0.858	p = 0.041*	p = 0.937	p = 0.788